AffaMed Digital Initiates Clinical Study for AMD201 at Beijing Tiantan Hospital
AffaMed Digital, a company wholly owned by AffaMed Technologies—a joint venture between AffaMed Therapeutics and...
Provincial Budgets Highlight Top Earning Hospitals in China for 2023
Provincial governments have revealed the budget for provincial hospitals’ expected income during 2023, offering a...
Corxel Pharmaceuticals’ OC-01 Nasal Spray Approved as Urgently Needed Drug in Hainan
Shanghai-based Corxel Pharmaceuticals (CORXEL), supported by RTW Investments, has announced that its OC-01 (varenicline) nasal...
Harbour BioMed’s Nona Biosciences Partners with ExeVir Bio to Explore Infectious Disease Sector
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...
AbbVie’s China General Manager Ou Silang Steps Down, Intercon’s Colzi to Take Interim Role
Ou Silang, Vice President and China General Manager of US pharmaceutical major AbbVie (NYSE: ABBV),...
Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for Two Clinical Trials
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) has announced two clinical trial approvals from the National...
Everest Medicines’ Nefecon NDA Accepted for Review by Singapore’s HSA
China-based Everest Medicines (HKG: 1952) has announced that the Health Sciences Authority (HSA) of Singapore...
Hutchison China Meditech Initiates Two Phase II Studies for HMPL-453 and Orpathys
China-based Hutchison China Meditech (HutchMed, NASDAQ: HCM, HKG: 0013) has announced that the first subjects...
Evopoint Biosciences Partners with Merck for Phase Ib/II Study Combining XNW5004 and Keytruda
China-based Evopoint Biosciences has announced a collaboration agreement with US major Merck Sharp & Dohme...
AstraZeneca and HKSTP Expand Collaboration with MoU to Support Start-Ups
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) and Hong Kong Science and Technology Parks Corp....
CStone Pharmaceuticals’ Sugemalimab Files for New Indication with NMPA for Esophageal Cancer
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has...
Biosion Receives FDA Approval for Phase II Study of TSLP mAb BSI-045B
Global, clinical-stage biotech company Biosion, dedicated to developing antibody-based therapies for immune and oncologic diseases,...
Shanghai Best-Link Bioscience Secures $29 Million in Series A Financing for Nano Drug Innovation
Shanghai Best-Link Bioscience, LLC, a leading nano drug and drug delivery-focused enterprise based in Shanghai,...
OncoSec Medical’s TAVO-EP Combo Misses Primary Endpoint in Melanoma Trial
US-based OncoSec Medical Inc., (OTCMKTS: ONCSQ), majority-owned by China-based Grand Pharmaceutical Group Ltd (HKG: 0512),...
Legend Biotech Corporation Appoints Industry Veterans to Strategic Advisory Board
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced the formation of a strategic advisory board...
Beijing-Tianjin-Hebei Alliance Completes VBP Tender for Coronary Intervention Devices with 78.29% Price Cut
The Beijing-Tianjin-Hebei “3+N” allied region has completed a volume-based procurement (VBP) tender for coronary catheters,...
Jacobio Pharma Receives Approval for Phase I/IIa Study of LIF mAb in Advanced Solid Tumors
China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to conduct a Phase...
Nanjing Zenshine Pharmaceuticals’ ZX-7101A Meets Primary Endpoint in Phase II Influenza Study
China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd announced that a Phase II...
WuXi Advanced Therapies (WuXi ATU) Closes Manufacturing Facilities in Shanghai Due to Market Changes
Media reports indicate that WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused Contract...
Shenzhen Hepalink’s Subsidiary Techdow USA Secures Distribution Rights for ANDA-Approved Drug
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its wholly owned...